|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-9-24
|
|
pubmed:abstractText |
Zidovudine (ZDV) and lamivudine (3TC) metabolism to triphosphates (TP) is necessary for antiviral activity. The aims of this study were to compare ZDV-TP and 3TC-TP concentrations in adolescents receiving twice daily (BID) and once daily (QD) regimens and to determine the metabolite concentrations of ZDV and 3TC during chronic therapy on a QD regimen. Human immunodeficiency virus-infected patients (12 to 24 years) taking ZDV (600 mg/day) and 3TC (300 mg/day) as part of a highly active antiretroviral therapy regimen received QD and BID regimens of ZDV and 3TC for 7 to 14 days in a crossover design. Serial blood samples were obtained over 24 h on the QD regimen. Intracellular mono-, di-, and triphosphates for ZDV and 3TC were measured. The median ratio of BID/QD for ZDV-TP predose concentrations was 1.28 (95% confidence interval [CI] = 1.00 to 2.45) and for 3TC-TP was 1.12 (95% CI = 0.81 to 1.96). The typical population estimated half-lives (+/- the standard error of the mean) were 9.1 +/- 0.859 h for ZDV-TP and 17.7 +/- 2.8 h for 3TC-TP. Most patients had detectable levels of the TP of ZDV (24 of 27) and 3TC (24 of 25) 24 h after dosing, and half-lives on a QD regimen were similar to previously reported values when the drugs were given BID. Lower, but not significantly different, concentrations of ZDV-TP were demonstrated in the QD regimen compared to the BID regimen (P = 0.056). Although findings were similar between the BID and QD groups, the lower concentrations of ZDV and the number of patients below the level of detection after 24 h suggests that ZDV should continue to be administered BID.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-10558940,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-10563709,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-11796359,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-14523272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-14693537,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-15040643,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-15216461,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-1969115,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-1977080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-2035995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-2926164,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-7477218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-7616988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-7913730,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-8203866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-8902065,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-8913483,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-9292587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-9756772,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17664328-9787687
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
pubmed-author:CapparelliEdmundE,
pubmed-author:FlynnPatricia MPM,
pubmed-author:HeckmanBarbaraB,
pubmed-author:KnappKatherine MKM,
pubmed-author:LindseyJane CJC,
pubmed-author:MartinezJaimeJ,
pubmed-author:McNamaraJamesJ,
pubmed-author:PACTG P1012 Team,
pubmed-author:RobbinsBrianB,
pubmed-author:RodmanJohnJ,
pubmed-author:RodriguezJose FJF,
pubmed-author:SerchuckLeslieL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3516-22
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17664328-Adolescent,
pubmed-meshheading:17664328-Adult,
pubmed-meshheading:17664328-Anti-HIV Agents,
pubmed-meshheading:17664328-Area Under Curve,
pubmed-meshheading:17664328-CD4 Lymphocyte Count,
pubmed-meshheading:17664328-Child,
pubmed-meshheading:17664328-Cross-Over Studies,
pubmed-meshheading:17664328-Drug Combinations,
pubmed-meshheading:17664328-Female,
pubmed-meshheading:17664328-Half-Life,
pubmed-meshheading:17664328-Humans,
pubmed-meshheading:17664328-Lamivudine,
pubmed-meshheading:17664328-Male,
pubmed-meshheading:17664328-Monocytes,
pubmed-meshheading:17664328-Phosphorylation,
pubmed-meshheading:17664328-Zidovudine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.
|
|
pubmed:affiliation |
Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN 38105, USA. pat.flynn@stjude.org
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
